Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
ZEPP Catalyst Timeline
Dated clinical, regulatory and corporate events for Zepp Health Corporation American depositary shares, each representing sixteen Class A ordinary shares
Past FDA Catalysts and PDUFA Decisions
How ZEPP actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
No drug pipeline
Zepp Health Corporation is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every ZEPP program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Yu PengtaoOfficer (Chief Industrial Designer) | Sell | -4,251 98,491 held | $4.09 | 09/24/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ZEPP
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ZEPP for Q3 2026. | ||||
Ownership Trends
ZEPP Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How ZEPP ranks across every disease it competes in
ZEPP News
Zepp Health Corporation to Report Third Quarter 2026 Financial Results on November 22, 2026
Zepp Health Corporation will report its third quarter 2026 financial results on November 22, 2026. A conference call is scheduled for 8:30 p.m. ET on the same day. The company, known for its Amazfit brand, has a strong global presence with over 200 million devices shipped.
Read more →Zepp Health Corporation Reports Second Quarter of 2026 Unaudited Financial Results
Zepp Health Corporation reported its unaudited financial results for Q2 2026, showing a revenue increase of 6.9% year-over-year to US$63.5 million. Despite the revenue growth, the company experienced a net loss of US$11.3 million, up from US$7.7 million in the previous year, due to foreign-exchange impacts and increased investments in R&D and marketing. The gross margin improved to 37.4%, reflecting a favorable product mix, although challenges remain with supply constraints and rising component costs.
Read more →Zepp Health Corporation to Report Second Quarter 2026 Financial Results on September 1, 2026
Zepp Health Corporation will report its second quarter 2026 financial results on September 1, 2026. A conference call is scheduled for 9:30 p.m. ET, where management will discuss the results. The call will be accessible via phone and a live webcast. Zepp Health is recognized for its innovative health technology products.
Read more →Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training
Amazfit has introduced the Helio Strap Pro, designed for body-worn movement intelligence in HYROX and hybrid training. However, the article provides minimal details about the product's features or benefits, leaving readers with questions about its market implications.
Read more →Zepp Health Corporation Reports First Quarter of 2026 Unaudited Financial Results
Zepp Health Corporation reported its unaudited financial results for Q1 2026, showing a revenue increase of 33.8% year-over-year to $51.5 million. The company launched several new products aimed at enhancing user engagement and performance. Despite a seasonal dip in consumer electronics, management expects continued growth in the upcoming quarter, with projected revenues between $63 million and $68 million.
Read more →Zepp Health Corporation to Report First Quarter 2026 Financial Results on June 8, 2026
Zepp Health Corporation will report its first quarter 2026 financial results on June 8, 2026. A conference call is scheduled for 9:30 p.m. ET on the same day, allowing stakeholders to access the results and insights. The company continues to lead in the smart wearables market, emphasizing its commitment to health technology.
Read more →Zepp Health Corporation Files 2025 Annual Report on Form 20-F
Zepp Health Corporation has filed its annual report on Form 20-F for the year ending December 31, 2025. The report is accessible on the company's investor relations website and the SEC's website. Zepp Health, known for its smart wearables, has successfully shipped over 200 million units globally.
Read more →Zepp Health Corporation Reports Fourth Quarter and Full Year 2025 Unaudited Financial Results
Zepp Health Corporation announced its fourth quarter and full year 2025 financial results, highlighting a strong revenue growth of 43% in Q4 reaching US$85.2 million. The gross margin improved to a record high of 40.4%, attributed to a more favorable product mix. Despite an adjusted operating loss of US$2.7 million, the company is optimistic about sustained growth into 2026, supported by strong sales during the holiday seasons and ongoing improvements in capital structure and inventory management.
Read more →Zepp Health Corporation Reports Third Quarter 2025 Unaudited Financial Results
Zepp Health Corporation reported strong financial results for Q3 2025, with revenues reaching $75.8 million, a 78.5% increase year-over-year. The company achieved breakeven in adjusted operating income and improved gross margins to 38.2%. Key drivers included the successful launch of new products, notably the Amazfit T-Rex 3 Pro. However, the company also faced challenges such as supply constraints and a delay in sales due to a natural disaster.
Read more →Zepp Health Corporation Reports Second Quarter 2025 Unaudited Financial Results
Zepp Health Corporation reported its second quarter 2025 unaudited financial results, highlighting a 46.2% year-over-year revenue growth primarily driven by Amazfit products. This marks the company's first overall revenue growth since 2021 and reflects successful strategic initiatives. The company expects continued strength in sales for the third quarter, with projections of US$72.0 million to US$76.0 million in revenue. Despite some decline in gross margin and ongoing adjusted operating losses, the firm remains optimistic about future growth stemming from its innovative product pipeline and effective marketing strategies.
Read more →Zepp Health Corporation Reports First Quarter 2025 Unaudited Financial Results
Zepp Health Corporation reported its unaudited financial results for the first quarter of 2025, showcasing a 10% year-over-year revenue growth from Amazfit products. Key drivers included the successful launches of new smartwatch models, despite challenges such as net losses and fixed expenses not being fully absorbed during the low sales season. The company highlighted improvements in gross margins and is optimistic about continued sales growth for upcoming product launches, alongside significant adjustments in supply chain strategy. However, there are ongoing supply constraints affecting certain product versions.
Read more →Zepp Health Corporation Reports Fourth Quarter and Full Year 2024 Unaudited Financial Results
Zepp Health Corporation reported its unaudited financial results for the fourth quarter and full year of 2024, indicating robust growth in revenue and gross margin despite prior year declines. The company achieved a 40.2% increase in Q4 revenue compared to the previous quarter, largely driven by the successful launch of the T-Rex 3 smartwatch. However, year-over-year comparisons showed a revenue drop of 28.3%, attributed to different product launch timing and macro headwinds. Zepp's cash position remains strong, with $111 million reported, suggesting potential for future investments.
Read more →Zepp Health Corporation Reports Third Quarter 2024 Unaudited Financial Results
Zepp Health Corporation announced its unaudited financial results for the third quarter of 2024, reporting revenues of $42.5 million, a decrease of 48.9% from the previous year. Despite a net loss of $13.3 million, the company experienced a positive trend with a 10% increase in Amazfit branded sales and achieved the highest gross margin in its history. Key product launches, particularly the T-Rex3 smartwatch, have been well-received, and the company is optimistic about sustained growth moving forward with a strong product pipeline and strategic direction.
Read more →Zepp Regains Compliance with NYSE Minimum Price Continued Listing Criterion
Zepp Health Corporation announced that it has regained compliance with the NYSE's minimum price continued listing criterion, following an earlier notification that its share price had fallen below compliance standards. The NYSE communicated this positive change in a letter dated October 2, 2024. This development marks a recovery for the company after it was previously below the compliance threshold due to a low average closing price of its American depositary shares over a consecutive trading period. Zepp Health continues to operate as a prominent player in the smart wearables and health technology market.
Read more →Zepp Health Corporation Announces Plan to Implement ADS Ratio Change
Zepp Health Corporation has announced a change in the ratio of its American depositary shares (ADSs) to Class A ordinary shares. The new ratio will increase from 1 ADS representing 4 shares to 1 ADS representing 16 shares, effectively initiating a one-for-four reverse ADS split. The change is set to take effect around September 16, 2024, subject to SEC approval. The company emphasizes that this adjustment will not affect the underlying ordinary shares, although it introduces complexities regarding fractional ADSs.
Read more →Zepp Health Corporation Announces Board Changes
Zepp Health Corporation has announced new appointments to its board of directors, effective September 1, 2024. Mr. Alain Lam, Mr. Mike Yan Yeung, and Mr. Meihui Fan join the board, bringing extensive experience in finance, operations, and technology. Resigning directors include Mr. De Liu, Ms. Yunfen Lu, and Mr. Xiaojun Zhang, with some continuing their roles in the company. The new appointments are expected to strengthen the company's leadership as it navigates the health technology sector.
Read more →Zepp Health Corporation Reports Second Quarter 2024 Unaudited Financial Results
Zepp Health Corporation reported its unaudited financial results for the second quarter of 2024, revealing revenues of $40.6 million and a net loss per share of $0.04. Although revenue saw a significant decrease from the same quarter last year, the company highlighted a sequential increase in self-branded product sales and achieved a historic high in gross margin. CEO Wang Wayne Huang expressed confidence in the company's transformation phase, noting the upcoming launch of new products and strategic marketing initiatives. However, the overall decline in revenue and units shipped underscores ongoing challenges for the company.
Read more →Zepp Health Corporation Reports First Quarter 2024 Unaudited Financial Results
Zepp Health Corporation reported its unaudited financial results for Q1 2024, posting revenues of US$39.8 million and a net loss of US$14.6 million. The company's gross margin reached a record high of 36.8%, driven by strong sales of self-branded products, which accounted for over 85% of total revenues. Despite these positive outcomes, the firm experienced significant declines in revenue and units shipped, attributed to a lack of new product launches and overall market conditions. The company remains committed to innovation and strategic investments to improve market presence moving forward.
Read more →Zepp Health Corporation Reports Fourth Quarter and Full Year 2023 Unaudited Financial Results
Zepp Health Corporation reported its unaudited financial results for the fourth quarter and full year of 2023, revealing a revenue of US$84.5 million, a decrease of 44% from the previous year. The company achieved a net loss of US$1.2 million but noted an all-time high gross margin of 34.7%. CEO Wayne Huang emphasized progress in strategic transformation and recent product launches, including the Amazfit Active series and Amazfit Helio Ring. Despite challenges, Zepp is focused on long-term competitiveness and innovation in the wearable technology sector.
Read more →Zepp Health Corporation Reports Third Quarter 2023 Unaudited Financial Results Amsterdam, the Netherlands
Zepp Health Corporation reported its third quarter 2023 unaudited financial results, highlighting a return to profitability with a net income of RMB3.0 million after a series of losses. Despite a significant year-over-year revenue decline of 50.1%, the company noted strong performance in its self-branded products, which contributed to the majority of revenue. The gross margin also reached a new high at 33.9%, demonstrating improved operational efficiency and successful product strategies. The company plans to leverage its technology and continue refining its product offerings to support future growth.
Read more →